Eom Pharmaceutical Holdings IncOTC Pink - Limited Information:IMUC
- LAST PRICE0.1979
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.1550/ 50
- Ask / Lots0.1979/ 50
- Open / Previous Close0.0000 / 0.1979
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eom Pharmaceutical Holdings Inc | 22.4M | -4.6x | --- |
Bioxytran Inc | 22.9M | -4.5x | --- |
Bullfrog AI Holdings, Inc. | 22.5M | -3.2x | --- |
Ayala Pharmaceuticals Inc | 23.0M | -0.1x | --- |
Neurosense Therapeutics Ltd | 23.2M | -1.6x | --- |
CERo Therapeutics Holdings Inc | 21.4M | -3.8x | --- |
Company Information
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their portfolio: EOM613 and EOM147. EOM613 is an investigational immunomodulator. EOM613 is a peptide-nucleic acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. EOM613 helps to suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells resulting in either further activation or suppression. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF.
Contact Information
- Headquarters
- 30721 Russell Ranch Road, Suite 140WESTLAKE VILLAGE, CA, United States 91362
- Phone
- 818-264-2300
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Operating Officer
- Eli Goldberger
- President, Chief Executive Officer, Director
- Irach Taraporewala
- Chief Financial Officer, Treasurer
- Wayne Danson
- Chief Scientific Officer
- Shalom Hirschman
- Independent Director
- Frank Douglas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 113.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.30 |
EPS | $-0.04 |
Book Value | $-0.01 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
